Brind.
  1. Agilent Technologies and Charles River Laboratories are both companies operating in the life sciences sector.

Charles River Targets 5-7% Revenue Growth Amid Strategic Overhaul

1 report, 1 independent Updated Sat 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Charles River Laboratories outlined a strategic framework called “Pathway to Purpose” during its Investor Day, setting financial targets through 2030. The company aims for 5% to 7% organic revenue growth, a low-double-digit non-GAAP earnings-per-share growth, and approximately a 24% non-GAAP operating margin. The company's modernization initiative is targeting at least $300 million in cumulative incremental savings between 2027 and 2030.

From themarketsdaily.com

Why it matters

Some supportBrind's analysis of the reports

The strategic overhaul focuses on three priorities: modernizing the company, strengthening its scientific portfolio, and growing through a customized client-centric approach. The modernization program, led by Chief Information Officer Mark Mintz, focuses on AI, automation, digitization, and enterprise optimization.

Both companies operate within the life sciences sector.

From themarketsdaily.com

Who's involved

  • Charles River LaboratoriesMajor US biomedical company undergoing strategic modernization.
  • ApolloDigital client engagement platform for Charles River Laboratories.
  • Mark MintzChief Information Officer and head of global shared services for Charles River Laboratories.

Keep exploring

Part of

Agilent Technologies and Charles River Laboratories are both companies operating in the life sciences sector. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped